Aibtl biopharma inc. acquired tt life company, valued at $8.33m, with 1.66m aibtl shares at $5 per share

Fremont, ca, april 18, 2024 (globe newswire) -- via newmediawire — abvc biopharma, inc. (nasdaq: abvc) ("company"), a clinical-stage biopharmaceutical company developing therapeutic solutions in ophthalmology, cns (central nervous systems), and oncology/hematology, announced today that the company's subsidiary aibtl biopharma inc. acquired tt life company, an established player in the precision medicine industry. the acquisition includes malaysian import trading company, direct sales company, and taiwanese direct sales company, which are estimated to be approximately equivalent to $8.33m. aibtl purchased 100% shares of tt life by swapping its 1.66m shares at $5 per share. this strategic move positions aibtl to expand its portfolio further and accelerate innovation in the rapidly growing precision medicine market while consolidating the financials, including the revenue, profit, and cash flow, with tt life.
ABVC Ratings Summary
ABVC Quant Ranking